![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
ML Pucci, LB Dick, KB Miller, CJ Smith and A Nasjletti
Department of Pharmacology, New York Medical College, Valhalla, USA.
We contrasted, in normotensive and hypertensive rats, the effect of L- arginine on isometric tension of phenylephrine-contracted rings of aorta bathed in Krebs' bicarbonate buffer on cyclic guanosine monophosphate content of aortic rings and on blood pressure. L-Arginine had no effect on isometric tension or cyclic guanosine monophosphate content of aortic rings from normotensive controls. Conversely, L- arginine (10(-5)-10(-3) mol/l) induced concentration-dependent relaxation of unrubbed and rubbed rings of thoracic and abdominal aorta and, as well, L-arginine (10(-3) mol/l) increased cyclic guanosine monophosphate in unrubbed and rubbed rings of thoracic aorta taken from hypertensive rats 7 to 14 days after aortic coarctation. Similar relaxations to L-arginine were seen in rings of thoracic and abdominal aorta from rats made hypertensive by infusion of angiotensin II for 7 to 8 days but not in rings of thoracic aorta from rats with aortic coarctation-induced hypertension of 28 to 42 days. Relaxant responses to L-arginine in rings of thoracic aorta from hypertensive rats 7 to 14 days after aortic coarctation were unaffected by pretreatment of rings with dexamethasone (10(-7) mol/l) or L-arginine (10(-4) mol/l) but were blunted by NG-nitro-L-arginine methylester (3 x 10(-4) mol/l) or methylene blue (10(-5) mol/l). Our results suggest that the vasorelaxant effects of L-arginine in aortic rings from hypertensive rats 7 to 14 days after aortic coarctation and 7 to 8 days after commencing angiotensin II infusion are mediated by nitric oxide.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  D. K. Miller, P. A. Crooks, G. Zheng, V. P. Grinevich, S. D. Norrholm, and L. P. Dwoskin Lobeline Analogs with Enhanced Affinity and Selectivity for Plasmalemma and Vesicular Monoamine Transporters J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1035 - 1045. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. Miller, E. H. F. Wong, M. D. Chesnut, and L. P. Dwoskin Reboxetine: Functional Inhibition of Monoamine Transporters and Nicotinic Acetylcholine Receptors J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 687 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Borasio, W. Robberecht, P. N. Leigh, J. Emile, R. J. Guiloff, F. Jerusalem, V. Silani, P. E. Vos, J.H.J. Wokke, T. Dobbins, et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis Neurology, August 1, 1998; 51(2): 583 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Guan, V. Cachofeiro, M. L. Pucci, P. M. Kaminski, M. S. Wolin, and A. Nasjletti Nitric Oxide and the Depressor Response to Angiotensin Blockade in Hypertension Hypertension, January 1, 1996; 27(1): 19 - 24. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
